New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
09:53 EDTJNJ, SYK, ZMHBiomet results positive for large reconstructive players, says Wells Fargo
After privately-held Biomet reported knee growth accelerated to 8% and hip growth declined slightly to 4% in its second quarter, Wells Fargo said the results are a positive sign for the reconstructive market. Wells added that it expects larger reconstructive industry companies, including Zimmer (ZMH), Stryker (SYK), and Johnson & Johnson (JNJ), to trade higher following Biomet's results.
News For ZMH;SYK;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
10:00 EDTZMHOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:32 EDTZMHZimmer downgraded to Hold from Buy at Brean Capital
Brean Capital downgraded Zimmer to Hold saying uncertainty over 2016 earnings potential following the Biomet acquisition is likely to linger for several quarters. Brean sees little room for multiple expansion pending greater clarity.
June 24, 2015
13:14 EDTZMHZimmer trading resumes, shares up 96c to $113.66
13:11 EDTZMHZimmer Biomet sees 2015 constant currency revenue growth 1.5%-2.0%
Subscribe for More Information
13:09 EDTZMHZimmer announces completion of Biomet acquisition
Subscribe for More Information
13:00 EDTZMHZimmer trading halted, pending news
Subscribe for More Information
11:54 EDTZMHSmith & Nephew to acquire Zimmer Unicondylar Knee system in U.S. market
Subscribe for More Information
11:32 EDTZMHZimmer required by FTC to divest assets as condition of Biomet acquisition
Subscribe for More Information
June 22, 2015
07:43 EDTSYKStryker management to meet with Deutsche Bank
Meeting to be held in Paris on June 22 hosted by Deutsche Bank.
June 17, 2015
07:21 EDTJNJGeneric ADHD drugs still sold despite FDA non-equivalance finding, NYT reports
The FDA announced last November that two generic versions of Johnson & Johnson's (JNJ) Concerta ADHD drug, one made by Mallinckrodt (MNK) and the other by UCB, could no longer be considered the equivalent of the branded drug after tests and analyses suggested that their effectiveness began to wear off much more quickly, but the drugs are still being sold despite an FDA mandated deadline having passed for the companies to either prove the drugs were equivalent or remove them from the market, said The New York Times. The report noted a third generic product, sold by Actavis (AGN), was found to be equivalent to the branded Concerta. Reference Link
June 16, 2015
07:56 EDTZMHZimmer management to meet with Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use